AI/ML in Drug Development
ACRO’s AI/ML Committee brings together member company subject matter experts engaged in the development and use of AI/ML tools in the design, conduct, oversight, and analysis of clinical trials.
Thought Leadership
ACRO’s Artificial Intelligence/Machine Learning Committee produced the following Principles Statement in December 2023. The committee represents the industry to regulators and policymakers considering regulation and legislation that could impact the use of AI/ML in drug development.
ACRO members are invested in ensuring the development and stewardship of responsible AI. In a 2024 survey of ACRO member companies, 100% of ACRO members are developing/utilizing artificial intelligence to improve organizational efficiency including streamlining data management, assisting with project and study start-up, site selection, and more.